News | kaléo

Press

With Life-Threatening Allergies Diagnosed in Infancy, kaléo Announces Availability of First and Only FDA-Approved Epinephrine Auto-Injector (EAI) for Infants and Toddlers Weighing 16.5 to 33 Pounds (7.5 to 15 kilograms) April 26, 2018
NASCAR Driver Elliott Sadler Teams Up with kaléo about AUVI-Q® (Epinephrine Injection, USP) to Raise Awareness of Life-Threatening Allergies April 18, 2018
EVZIO® (naloxone HCl injection, USP) Auto-Injector Now Available to Patients in Select States Without a Prescription Through Kaléo’s New Virtual Standing Order Pilot Program and to Government Agencies at a Direct Purchase Price April 5, 2018
Cabell-Huntington Health Department and the City of Huntington Fire Department Officials Named Co-Recipients of the 2017 kaléo Cares Award February 21, 2018
More than 5000 Lives Reported Saved with Help of EVZIO® (naloxone HCl injection) Auto-injectors January 11, 2018
U.S. FDA Approves Kaléo’s AUVI-Q® (Epinephrine Injection, USP) 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children November 20, 2017
Kaléo Along with National Advocacy Organizations Launch the “No Appetite for Bullying” Initiative October 24, 2017
Kaléo Donates Thousands of AUVI-Q® (epinephrine injection, USP) and EVZIO® (naloxone HCl injection) Auto-injectors to Hurricane Harvey Relief Efforts September 1, 2017
Kaléo Announces AUVI-Q® (epinephrine injection, USP) Charitable Donation Program for All Public Elementary Schools in the United States August 7, 2017
U.S. FDA Grants Priority Review for an Epinephrine Auto-Injector in Development by Kaléo Specifically for Infants and Small Children July 27, 2017